Tradestie Institutional Equity Comparison Engine
BHVN vs BBIO โ Head-to-Head Terminal
6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.
Pillar 1 Executive Scorecard & Category Winner Tally
BHVN Overall Edge
BHVN Captures Institutional Edge (2โ1 Pillars ยท 4โ4 Matrix Metrics)
Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Biohaven Ltd. (BHVN) driven by superior Growth & Margin, Momentum & Technical while BBIO counters with relative strength in Options & Structure. Fundamentally, BHVN trades at N/M Forward P/E with 0.0% operating margin (+0.0% YoY revenue) versus BBIO at N/M Forward P/E and -37.3% operating margin (+192.6% YoY). In options structure, BHVN sits in CONSOLIDATION (18th %ile IV; Dealer Gamma Walls on Pro) against BBIO sits in CONSOLIDATION (3rd %ile IV; Dealer Gamma Walls on Pro).
Valuation Winner
Tie
BHVN N/M vs BBIO N/M Fwd P/E
Growth & Margin Winner
BHVN
Op Margin 0.0% vs -37.3% ยท YoY +0.0% vs +192.6%
Momentum & Technical Winner
BHVN
1Y +72.1% vs +18.6% ยท 52W Pos 59% vs 48%
Options & Structure Winner
BBIO
CONSOLIDATION (18th %ile IV) vs CONSOLIDATION (3rd %ile IV)
BHVN
NYSE
Biohaven Ltd.
Pharmaceutical Preparations
$13.90
+0.62% 1D
Market Cap
$2.1B
1M Return
+28.99%
1Y Return
+72.09%
Forward P/E
N/M
Unified AI Score
42.1 / 100
HOLD
Tech 15.0
Fund 42.0
Flow 68.0
Mom 50.0
BBIO
NASDAQ
BridgeBio Pharma, Inc. Common Stock
Pharmaceutical Preparations
$77.18
-1.43% 1D
Market Cap
$15.2B
1M Return
+16.25%
1Y Return
+18.63%
Forward P/E
N/M
Unified AI Score
44.5 / 100
HOLD
Tech 19.0
Fund 40.0
Flow 66.0
Mom 40.0
Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)
1Y Indexed Return:
BHVN +72.09%
BBIO +18.63%
Spread: +53.46 pp (BHVN Lead)
Pillar 3 Operating Profitability Benchmark (Trailing 12-Month)
BHVN TTM Op. Margin: 0.0%
BBIO TTM Op. Margin: -37.3%
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on BHVN vs BBIO. Trailing 12-month operating profitability (BHVN 0.0% vs BBIO -37.3%) and valuation multiples (BHVN N/M vs BBIO N/M Forward P/E) are benchmarked directly in Pillar 4 below.
Pillar 4 Head-to-Head Fundamental & Valuation Matrix
| Institutional Metric | BHVN | BBIO | Criterion | Row Winner |
|---|---|---|---|---|
| Market Capitalization Scale | $2.1B | $15.2B | Larger Scale | BBIO |
| Trailing P/E Ratio Valuation | N/M | N/M | Lower Multiple | Tie |
| Forward P/E Ratio Valuation | N/M | N/M | Lower Multiple | Tie |
| Revenue Growth (YoY) Growth | +0.0% | +192.6% | Higher Growth | BBIO |
| Operating Margin (TTM) Profitability | 0.0% | -37.3% | Higher Margin | BHVN |
| Net Profit Margin Profitability | 0.0% | -59.8% | Higher Margin | BHVN |
| Return on Equity (ROE) Capital Efficiency | -799.5% | -1789.7% | Higher ROE | BHVN |
| 52-Week Range Position Momentum | 59% ($8โ$18) | 48% ($62โ$93) | Stronger Trend | BHVN |
| Beta / 30D Volatility Risk Regime | 1.41ฮฒ ยท 111% Vol | 0.88ฮฒ ยท 38% Vol | Lower Realized Risk | BBIO |
| Unified Institutional Score Composite Signal | 42.1 / 100 (HOLD) | 44.5 / 100 (HOLD) | Higher Composite | BBIO |
Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor
Full BHVN vs BBIO Buy Guide
BHVN
CONSOLIDATION
91d in phase ยท OBV NEUTRAL
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
IV Percentile
18th %ile
IV Regime
Compressed (<25th %ile)
BBIO
CONSOLIDATION
91d in phase ยท OBV ACCUMULATION
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
IV Percentile
3rd %ile
IV Regime
Compressed (<25th %ile)
Pillar 6 90-Day Technical & R&D Innovation Disclosures
Corporate R&D & Foundry Tracker
Neither BHVN nor BBIO registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.